Merck, 476475-500UG, PKC Inhibitor, EGF-R Fragment 651-658, Myristoylated

General description
Epidermal growth-factor receptor (EGF-R) conserved sequence which is identical to v-erbB (95-102). An N-terminal myristoylated membrane-permeable, reversible, and substrate competitive inhibitor that inhibits protein kinase C (IC₅₀ = 5 µM) in intact cells.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
PKC
Product does not compete with ATP.
Reversible: yes
Target IC₅₀: 5 µM against protein kinase C
Packaging
Yes
Physical form
Supplied as a trifluoroacetate salt.
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 2 months at -20°C.
Other Notes
Myr-N-Arg-Lys-Arg-Thr-Leu-Arg-Arg-Leu-OH
Ward, N.E., and O’Brian, C.A. 1993. Biochemistry32, 11903.
O’Brian, C.A., et al. 1991. Invest. New Drugs 9, 169.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)